A .gov website belongs to an official government
organization in the United States.
Secure .gov websites use HTTPS
A lock ( ) or https:// means
you've safely connected to the .gov website. Share sensitive
information only on official, secure websites.
Advisory Committee on Immunization Practices (ACIP)
The ACIP is a group of medical and public health experts that develops recommendations on the use of vaccines in the civilian population of the United States. The ACIP holds three meetings each year at the Centers for Disease Control and Prevention (CDC), in Atlanta, Georgia to make vaccine recommendations. Meetings are open to the public and available online via webcast. More information on ACIP is available at: https://www.cdc.gov/vaccines/acip/index.html.
Thompson, M. G. (2018). Influenza vaccine effectiveness in preventing influenza-associated hospitalizations during pregnancy: a multi-country retrospective test negative design study, 2010-2016. https://stacks.cdc.gov/view/cdc/61468
Thompson, Mark G.. Influenza vaccine effectiveness in preventing influenza-associated hospitalizations during pregnancy: a multi-country retrospective test negative design study, 2010-2016. 2018. https://stacks.cdc.gov/view/cdc/61468.
Thompson, Mark G. Influenza vaccine effectiveness in preventing influenza-associated hospitalizations during pregnancy: a multi-country retrospective test negative design study, 2010-2016. 2018, Stacks. https://stacks.cdc.gov/view/cdc/61468.
October 25, 2018
|
ACIP: Human Papillomavirus (HPV)
No Description
Public Domain
Chesson, H. W. (2018). Impact and economic analysis : summary of three models of 9-valent HPV vaccination among adults up to age 45 years in the United States. https://stacks.cdc.gov/view/cdc/61463
Chesson, Harrell W.. Impact and economic analysis : summary of three models of 9-valent HPV vaccination among adults up to age 45 years in the United States. 2018. https://stacks.cdc.gov/view/cdc/61463.
Chesson, Harrell W. Impact and economic analysis : summary of three models of 9-valent HPV vaccination among adults up to age 45 years in the United States. 2018, Stacks. https://stacks.cdc.gov/view/cdc/61463.
Kroger, A. T. (2018). ACIP general best practice guidelines for immunization – background and posted revisions since April 2017. https://stacks.cdc.gov/view/cdc/61466
Kroger, Andrew T.. ACIP general best practice guidelines for immunization – background and posted revisions since April 2017. 2018. https://stacks.cdc.gov/view/cdc/61466.
Kroger, Andrew T. ACIP general best practice guidelines for immunization – background and posted revisions since April 2017. 2018, Stacks. https://stacks.cdc.gov/view/cdc/61466.
October 25, 2018
|
ACIP: Human Papillomavirus (HPV)
No Description
Public Domain
Markowitz, L. E. (2018). Expanded age range for 9-valent HPV vaccine : Work Group plans and policy considerations. https://stacks.cdc.gov/view/cdc/61464
Markowitz, Lauri E.. Expanded age range for 9-valent HPV vaccine : Work Group plans and policy considerations. 2018. https://stacks.cdc.gov/view/cdc/61464.
Markowitz, Lauri E. Expanded age range for 9-valent HPV vaccine : Work Group plans and policy considerations. 2018, Stacks. https://stacks.cdc.gov/view/cdc/61464.
Greenberg, D. (2018). Safety and immunogenicity in adults of revaccination with Adacel® vaccine 8-12 years after a previous dose. https://stacks.cdc.gov/view/cdc/61474
Greenberg, David. Safety and immunogenicity in adults of revaccination with Adacel® vaccine 8-12 years after a previous dose. 2018. https://stacks.cdc.gov/view/cdc/61474.
Greenberg, David Safety and immunogenicity in adults of revaccination with Adacel® vaccine 8-12 years after a previous dose. 2018, Stacks. https://stacks.cdc.gov/view/cdc/61474.
Mercer, M. (2018). Study GRC88 : safety and immunogenicity of Fluzone® quadrivalent vaccine 0.5-ml dose for children 6 through 35 months of age. https://stacks.cdc.gov/view/cdc/61469
Mercer, Monica. Study GRC88 : safety and immunogenicity of Fluzone® quadrivalent vaccine 0.5-ml dose for children 6 through 35 months of age. 2018. https://stacks.cdc.gov/view/cdc/61469.
Mercer, Monica Study GRC88 : safety and immunogenicity of Fluzone® quadrivalent vaccine 0.5-ml dose for children 6 through 35 months of age. 2018, Stacks. https://stacks.cdc.gov/view/cdc/61469.
Markowitz, Lauri E.. Expanded age range for 9-valent HPV vaccine : background for policy considerations. 2018. https://stacks.cdc.gov/view/cdc/61461.
Markowitz, Lauri E. Expanded age range for 9-valent HPV vaccine : background for policy considerations. 2018, Stacks. https://stacks.cdc.gov/view/cdc/61461.
October 24, 2018
|
ACIP: Child/Adolescent Immunization
No Description
Public Domain
Robinson, C. L., & Bernstein, H. H. (2018). 2019 Recommended immunization schedule for children and adolescents aged 18 years or younger. https://stacks.cdc.gov/view/cdc/61455
Robinson, Candice L. and Henry H. Bernstein. 2019 Recommended immunization schedule for children and adolescents aged 18 years or younger. 2018. https://stacks.cdc.gov/view/cdc/61455.
Robinson, Candice L., and Henry H. Bernstein 2019 Recommended immunization schedule for children and adolescents aged 18 years or younger. 2018, Stacks. https://stacks.cdc.gov/view/cdc/61455.
Gierke, R. (2018). Estimating impact of 13-valent pneumococcal conjugate vaccine (PCV13) on pneumococcal pneumonia among U.S. adults. https://stacks.cdc.gov/view/cdc/61450
Gierke, Ryan. Estimating impact of 13-valent pneumococcal conjugate vaccine (PCV13) on pneumococcal pneumonia among U.S. adults. 2018. https://stacks.cdc.gov/view/cdc/61450.
Gierke, Ryan Estimating impact of 13-valent pneumococcal conjugate vaccine (PCV13) on pneumococcal pneumonia among U.S. adults. 2018, Stacks. https://stacks.cdc.gov/view/cdc/61450.
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC)
cannot attest to the accuracy of a non-federal website.
Linking to a non-federal Website does not constitute an
endorsement by CDC or any of its employees of the sponsors or the
information and products presented on the website.
You will be subject to the destination website's privacy
policy when you follow the link.
CDC is not responsible for Section 508 compliance
(accessibility) on other federal or private websites.
For more information on CDC's web notification policies, see Website Disclaimers.